Frog monocular horizontal optokinetic nystagrnus (H-OKN) displays a di~rectional asymmetry. Stimulation in the temporal-nasal (T-N) direction is the only efficient to evoke the reflex. The nasal-temporal (N-T) stimulation is not able to provoke any eye movements.
In previous studies, an attempt to find a pharmacological explanation far the mechanism underlying H-OKN asymmetry was done. It was shown that GABAergic, cholinergic and glutamatergic systems are involved in this function and that drugs affecting these systems intervene at retinal as well as central pretectal levels.
When GABAergic and cholinergic nicotinic antagonists were injected into the viewing recorded eye, they provoked the abolition of the H-OKN elicited by visual stimulation of this eye (Bonaventure, Jardon, Wioland, Yiicel & Rudolf, 1988; Yficel, Jardon, Kim & Bonaventure, 1990) . These results correlate with the modifications of the spatial organization of the retinal input observed in the same experimental conditions (Bonaventure, Wioland & Jardon, 1986; Bonaventure, Jardon, Wioland & Rudolf, 1987; Ariel & Rosenberg, 1991) .
Moreover these drugs provoke the appearance of a N-T component, suppressing the H-OKN asymmetry when acting on pretectal structures, either by systemic administration or by microinjections directly into the pretectal nuclei (Yiicel et al., 1990; Jardon, Yiicel & Bonaventure, 1992; . The involvement of ACh in the OKN origin was also demonstrated in other structures: microinjections of carbachol into the cerebellar flocculus has provoked the acceleration of the building up of the slow phase velocity OKN in the rabbit (Tan, Collewijn & Van der Steen, 1992 , 1993 . It was also shown that GABAB could have an inhibitory effect on OKN: administration of baclofen could reduce the optokinetic gain when injected either intramuscularly or intracerebroventicularly in the rat (Niklasson, Tham, Larsby & Eriksson, 1994) .
On the opposite (Jardon & Bonaventure, 1995) , it was shown that dopamine, when administered either by systemic or intrapretectal route was without apparent effect on frog visual monocular H-OKN asymmetry. The slow phase velocity gain of the T-N component was hardly modified compared to that of control; it was just slightly increased, especially at the lowest drum speeds, when the drug was injected directly into the pretectum. The fast phase frequency was slightly reduced. A stimulation in the N-T direction never induced an OKN.
Conversely, Piribedil (Servier) a dopamine agonist which is commonly used in Parkinson disease (Rondot, Bathien & Ribadeau-Dumas, 1975; Truelle, Chanelet, Bastard, Six & Emile, 1979) , provoked the appearance of a N-T component, suppressing the monocular OKN asymmetry. This was observed when Piribedil was injected into the open eye, the closed eye or directly into the pretectum. These conflicting results obtained with dopamine on the one hand and with Piribedil on the other hand are not easily understandable. Indeed, dopamine activates both D~ and D2 receptors since Piribedil itself activates D2 receptors, its metabolite showing a large affinity for the D~ receptors. Then, Piribedil displays a "dopamine like" profile with a direct action on receptors (Schmitt, Laubi6, Poignant, Krikorian, Evrard, Freyria & Arnaud, 1978) . Moreover, in the striatum, tritiated-sulpiride which specifically binds with the D2 receptors, was displaced by dopamine as well as by the D 2 agonists: in this experimental condition Piribedil was more active than dopamine (Woodruff & Freedman 1982) . In the rat brain Piribedil displaced the D2 antagonist, tritiated spiroperidol, whereas it had no effect on the specific D~ antagonist tritiated SCH 23390 (G. Kato, cited by Evrard, 1991) .
These experiments well confirm that Piribedil can be considered as an agonist of dopamine, especially acting on the D2 receptors.
In this framework, how can our apparent contradictory results be explained? Different hypotheses can be suggested, specifically Piribedil, which binds with the D 2 dopamine receptors, could also bind with receptors which are not dopamine receptors.
In order to demonstrate this hypothesis, we have studied the effects of Piribedil on H-OKN when the dopamine receptors were blocked. The strong neuroleptic haloperidol, a non-specific dopamine antagonist was used for this purpose. The most probable candidates to account for the Piribedil effect on OKN are the cholinergic muscarinic binding sites. It was indeed shown (Kato cited by Evrard, 1991) that Piribedil can displace tritiated pirenzepine, a muscarinic M I ligand from its fixation sites. Even if this effect is relatively weak, it suggests that Piribedil could have a direct effect upon cholinergic muscarinic receptors. Nevertheless this weak affinity for the muscarinic receptor (ICs0 3.6 x 10 -5 M) is in the range of the affinity of the "first generation" of ACh muscarinic ligands, i.e. muscarine and scopolamine. Like Piribedil, muscarine provoked the appearance of a N-T component at the same range of concentrations than those of Piribedil . Thus, we have also studied the effect of Piribedil on monocular H-OKN, when the cholinergic muscarinic receptors were blocked by atropine a muscarinic antagonist.
In a first part of this work, the effects of an injection of haloperidol on the frog monocular OKN were studied and the effects of a subsequent administration of Piribedil at various concentrations following that of haloperidol were analysed. In a second part, we have studied, the effects of an injection of atropine at various concentrations, carried out before or after that of *It was previously shown that drugs injected into the closed eye are conveyed by the blood stream to central structures, as after systemic injections.
Piribedil, knowing that atropine injected alone, does not modify the monocular H-OKN .
METHODS
Monocular eye OKN was recorded in frogs (Rana esculenta) by the magnetic coil system in head restrained animals. The technique has been described in detail elsewhere (Jardon & Bonaventure, 1995) . The frog was placed at the centre of the magnetic field in an optokinetic drum. The rotation speeds were constant and the drum was alternatively rotated clockwise and counterclockwise to prevent habituation. The stimulation speeds were 1, 3, 6 and 9 deg/sec.
The slow phase speed was measured from eye movement tracings using the cumulative curve of at least three successive slow phases at steady state after elimination of the eye resetting fast phases. The velocity gain (the ratio of the slow phase speed to the stimulus speed) as well as the eye resetting fast phase frequency (beats/20 see) were analysed.
The disappearance of the N-T component following the successive injection of Piribedil and atropine was admitted if the slow phase was no more measurable. Its appearance, following the successive injection of atropine and Piribedil was admitted when two successive slow phases separated by a fast phase were recorded.
Two series of experiments were carried out. In the first, frogs received a first injection of haloperidol and a second of Piribedil when the effect of the first drug reached maximum. In the second one, frogs received an injection of Piribedil which was preceded or followed by an administration of atropine. Recordings were carried out before and after each drug administration; these drugs were administered either intravitreally, intraperitoneally or directly into the pretectum contralateral to the open recorded eye. In the first case, 30/~1 of each solution were successively injected into the closed eye,* by a microsyringe under local anaesthesia; in the second one, 50 pl were injected into the abdomen of the frog.
The technique of microinjection into the nucleus lentiformis mesencephali (nLM) of the pretectum has been previously described (Jardon & Bonaventure, 1995) . Each drug was successively administered in a volume of 0.2 pl over 20 sec.
Haloperidol (Jansen) was diluted in saline. The 1 mM concentration used was determined from work realized in our laboratory on the chicken eye (Wioland, Rudolf & Bonaventure, 1990) and from pilot studies. Thus, 11.3/~g were injected into the closed eye and 75 ng into the pretectum.
Piribedil (Servier) was diluted in saline: concentrations used were 10, 1 and 0.1 mM when injected into the closed eye, and 0.1 mM only when injected into the pretectum. Thus, 118, 11.8 and 1.18 #g were respectively injected into the eye, and 7.8 ng into the pretecturn.
Atropine sulphate (Sigma) diluted in PBS was used at 50, 25, 10, 5 and 1 mM.
For purposes of data analysis a Wilcoxon signed rank test was used.
RESULTS

Control conditions
The monocular H-OKN was systematically recorded in each animal before rejection at four different drum speeds and in both directions of stimulation. The frog's viewing eye followed the stripes moving in the T-N direction. When the stimulation was applied in the N-T direction, no eye movement could be detected irrespective of the drum speed tested. Injection of the vehicle (saline) did not change the OKN when administered either into the eye (n = 3) [ Fig. I(A) ] or into the pretectum (n = 3) [ Fig. 2(A) ]. Surgical cannula implanted into the pretectum did not modify the control H-OKN.
Monocular eye H-OKN recordings following administration of haloperidol into the occluded eye or the pretectum
No spontaneous eye :movements were observed after haloperidol injection.
After injection of haloperidol 1 mM (n = 18) into the occluded eye the recording OKN was slightly modified [ Fig. I(B) ]. The slow phase velocity gain of the T-N component was slightly but significantly reduced for the lowest drum speeds (1 deg P < 0.005; 3 deg P < 0.01) but not for the highest ones [ Fig. 3(A, B, C) ]. The resetting fast phase frequency was also significantly reduced for all drum speeds used. For instance, the fast phase frequency was reduced from 5.2 beats/20 sec before injection, to 3.4 beats/20 sec following haloperidol for a stimulation speed of 6 deg/sec [ Fig. 4(A, B, C) ]. The stimulation in the N-T direction remained unable to evoke the reflex and the slow phase velocity gain was still almost nil.
After microinjection of haloperidol I mM (n = 6) [ Fig. 2(B) ] into the pretectum the slow phase velocity gain of the T-N component was not significantly modified compared to the control one, irrespective of the drum speed used [ Fig. 3(D) ].
The fast phase frequency was significantly (P < 0.005) reduced for all drum speeds except for a stimulation at 6 deg/sec [ Fig. 4(D) ]. Thus, for instance, for a stimulation speed at 9deg/sec, the frequency was 7.7 beats/20 sec before injection and was reduced to 5.8 beats/20 sec after haloperidol. Stimulations in the N-T direction were insufficient to provoke the reflex. Spontaneous recovery from the effects of haloperidol were not observed until 4 hr following the microinjection. 
Monocular eye H-OKN recordings following successive administration of haloperidol and Piribedil into the occluded eye or the pretectum
When the effect of the drug was maximal, 30 min after administration of haloperidol (1 mM) into the occluded eye, an injection of Piribedil was achieved by the same route, at various concentrations (0.1 mM n = 6; 1 mM n = 5; 10 mM n = 4) [ Fig. I(C) ].
For a T-N stimulation, no important change was noted in the monocular eye horizontal OKN when compared to that recorded following the first injection of haloperidol. The average velocity gain did not change significantly from previous values [ Fig. 3(A, B, C) ]. Only the strongest concentration of Piribedil (10 mM) had provoked an increase in the velocity gain at the lowest drum speeds (1 and 3 deg/sec) [ Fig. 3(A) ].
For the lowest concentration of Piribedil (0.1 mM) the resetting fast phase frequency was not significantly modified when compared to that of the OKN recorded after the first injection of haloperidol. It remained slowed down compared to that of the control [ Fig. 4(C) ]. On the other hand, the fast phase frequency increased at the two other concentrations reaching almost the values of the control (observed before haloperidol administration) [Fig. 4(A, B) ].
For a N-T stimulation, frogs displayed an eye H-OKN with slow phases following the stripe motion and resetting fast phases. This N-T component did not exist in controls as well as in H-OKN recorded after haloperidol injection. The average velocity gain increased significantly for all drum speeds tested (P < 0.005). The difference between the velocity gain of the H-OKN evoked by a T-N stimulation and that evoked by a N-T stimulation was no longer significant after the injection of Piribedil, irrespective of the concentration used [ Fig. 3(A, B, C) ]. This was true also for the measure of the fast phase frequency (not shown).
Piribedil (0.1 mM) was administered 10min after a microinjection of haloperidol (1 mM) into the pretectum by the same route [ Fig. 2(C) ].
The results are identical to those observed following successive administration of haloperidol and Piribedil into the eye [ Fig. 3(D) ]. For a stimulation in the T-N direction, the H-OKN was not modified, and the velocity gain remained unchanged, irrespective of the drum speed used. In the same manner, the fast phase frequency was not modified compared to that of the H-OKN measured after haloperidol administration [ Fig. 4(D) ].
Stimulations in the N-T direction provoked an H-OKN with slow phases and resetting fast phases. This H-OKN was totally similar (as far as gain and fast phase frequency are concerned) to that observed following T-N stimulations. (n = 13), nine frogs did not react to the N-T stimulation, while the four others displayed a symmetrical OKN, about 90 min after injection of both drugs. A concentration of atropine 5 mM (n -14) prevented the N-T component to appear in the OKN of eight frogs. The N-T component was present in the OKN of the six other frogs, but it disappeared after 1 hr in three of them. For concentration of atropine 1 mM (n = 10), four animals have only displayed the T-N component, while the six others have always presented a symmetrical OKN.
All these results were expressed in percentage of animals which have not displayed an OKN N-T component following simultaneous administration of atropine at various concentrations and of Piribedil 10 mM (Fig. 5) .
DISCUSSION
The horizontal frog OKN is asymmetrical in monocular viewing conditions, the T-N stimulation being only efficient, the N-T one being unable to evoke the reflex as already observed (Birukov, 1937; Dieringer & Precht 1982; Bonaventure, Wioland & Bigenwald, 1983) .
In a previous paper (Jardon & Bonaventure, 1995) we have demonstrated that dopamine does not modify this asymmetry and that the N-T component does not occur after administration of the drug. In the same manner, haloperidol, a non-specific dopamine antagonist, does not intervene in the monocular OKN asymmetry and does not provoke the appearance of an OKN after a stimulation in the N-T direction. Like dopamine, haloperidol, has provoked only mild effects on monocular H-OKN: when injected systemically, haloperidol has slightly reduced the slow phase velocity of the T-N component especially at the lowest drum speeds, while when injected into the pretectum it had no effect. Conversely, dopamine has provoked a little increase in the slow phase velocity when the drug was administrated directly into the pretectum. The fast phase frequency slightly decreased following dopamine injection, only at the highest drum speeds, while it decreased at all drum speeds tested after haloperidol.
The absence or minimal effects of dopamine as well as those of haloperidol on monocular H-OKN indicate that dopaminergic mechanisms do not seem to be involved in the monocular H-OKN asymmetry. This lack of effect is observed when the drugs are administered at retinal as at pretectal levels, though dopamine immunopositive cells and D~ and D2 binding sites are numerous in the retina (Ehinger, 1983; Elena, Denis, Kosina-Boix & Lapalus, 1989) . In the mesencephalic structures responsible for OKN, it is not known whether dopaminergic cells or receptors are present. The only data obtained were in the nBOR of the pigeon (Britto, Hanaassaki, Keyser & Karten, 1989) in which fibres and terminals were scarcely labelled with antibodies directed against tyrosine hydroxylase, the synthesizing enzyme of catecholamine. Nevertheless it is unclear whether doparnine or noradrenaline was synthesized from this enzyme, When acting on D2 receptors and using a protein G as a second messenger, dopamine is considered as an inhibitor amine in the central nervous system of vertebrates (Sandoval, Massieu, Araiza & Fernandez, 1989; Vallar & Meldolesi, 1989) . It is then possible that it may play a role in the maintenance of inhibition upon the N-T component as GABA or ACh through nicotinic receptors (Yficel et al., 1990; Bonaventure et al., 1988; . But this inhibitory effect remains hypothetical since haloperidol, barely modifies the frog monocular OKN, the N-T component remaining absent after injection of this dopamine antagonist.
Moreover, we were surprised to discover that Piribedil which is considered as a D2 dopamine agonist, and which is used as such in Parkinson disease, displayed characteristics other than those of dopamine in our experiments.
Irrespective of the route of administration (systemic or intrapretectal) Piribedil provoked the appearance of a N-T component suppressing the monocular OKN asymmetry. This observation is confirmed, even when the dopamine receptors have been blocked. Indeed, a previous administration of haloperidol which binds with the dopamine D~ and D2 receptors does not prevent the appearance of a N-T component of the monocular H-OKN following a subsequent administration of Piribedil. This is the case irrespective of the concentration of Piribedil used (10, 1 or 0.1 mM) or the site of injection (occluded eye or pretectum).
From the present experiment it can be concluded that Piribedil could act on receptors which are not dopaminergic receptors, these latter being blocked by haloperidol. In our experimental conditions Piribedil cannot displace haloperidol from its specific sites of fixation. It is suggested that haloperidol likely displays a higher affinity for the receptor than Piribedil, but it is also possible that the concentrations of Piribedil were too weak to displace haloperidol. However some observations realized by injecting lower concentrations of haloperidol (0.1 and 0.01 mM) compared to a higher one (10mM) showed no modifications of the effect of a subsequent administration of Piribedil. Thus it could occupy other sites than dopaminergic receptors in mesencephalic structures responsible for H-OKN.
An. histoautoradiographic study comparing the fixation of tritiated haloperidol versus tritiated Piribedil will help us to resolve this question. In the rat brain also, Piribedil does not always interact with dopamine receptors: while if it binds with the dopamine receptors in the substantia nigra and the nucleus accumbens, it does not in the striatum (Hall, Jenner & Marsden, 1983) .
In the retina also, Piribedil is not able to displace haloperidol from its sites of fixation: according to Doly (personal communication) this suggests that haloperidol and Piribedil do not systematically occupy the same sites of fixation in the retina. It could also be thought that Piribedil acts by increasing the blood flow; this hypothesis cannot be retained in so far as dopamine is also known to provoke the same effect.
Thus, what neuroreceptors could be bound with Piribedil to account for the disappearance of directional OKN asymmetry?
It is proposed that the cholinergic muscarinic system could be involved in the effect of Piribedil upon the monocular OKN. Certain symptoms of Parkinson disease are due not only to the degeneration of catecholaminergic containing neurons, but also to that of cholinergic neurons in the brainstem (Hirsch, Graybiel, Duyckaerts & Javoy-Agid, 1987) . Dopamine and its agonists exert anticholinergic effect through dopaminergic receptors located on cholinergic neurons at the nigro-striatal level. But this anticholinergic effect is not direct; therefore it cannot explain our results. Piribedil displays structural chemical analogies with ACh; moreover it is able to displace [3H]Pirenzepine (a M~ ligand) from its binding sites (Kato, cited by Evrard, 1991) , showing then that it can bind with muscarinic receptors. Though this effect is relatively weak (IC50 3.6 x 10 -5 M) it suggests that in our experiments, Piribedil may act like a muscarinic agonist. In a previous work, we have shown ) that muscarine has provoked the appearance of a N-T component in the monocular frog OKN at the same range of concentrations than those of Piribedil.
This hypothesis seems to be confirmed, since it was shown that an administration of atropine (a cholinergic muscarinic antagonist), which by itself has no effect upon the monocular H-OKN, antagonizes the disinhibitory effect of Piribedil. Atropine suppresses the N-T component when it is injected after Piribedil; it prevents its appearance when injected before Piribedil.
This experiment supports the hypothesis of a direct effect of Piribedil on muscarinic receptors, but it does not constitute direct proof. Indeed it cannot be excluded that atropine acts on a mechanism different from that on which Piribedil acts, and the effect obtained could be the result of the action of both antagonistic mechanisms. Only an histoautoradiographic study on the frog mesencephalon using tritiated Piribedil and atropine will allow us to elucidate whether atropine and Piribedil bind with the same receptors.
